日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study

POLARIS 研究中，合并症对接受帕博西尼治疗的激素受体阳性/人表皮生长因子受体 2 阴性 (HR+/HER2-) 晚期乳腺癌患者的临床结局和生活质量的影响

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.71788
Tripathy, Debu; Blum, Joanne L; Karuturi, Meghan S; McCune, Steven; Kurian, Sobha; Moezi, Mehdi M; Anderson, Daniel M; Ji, Yan; Pluard, Timothy J; Migas, John; Lakhanpal, Shailendra; Jepsen, Erin; Wang, Yao; Montelongo, Monica Z; Zhang, Zhe; Cappelleri, Joseph C; Gauthier, Eric; Rocque, Gabrielle B
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
Human
免疫/内分泌
发表日期：2026
文献求助 收藏

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer

OPERA：一项比较DHP107（口服紫杉醇）与静脉注射紫杉醇治疗HER2阴性复发或转移性乳腺癌患者的II期研究

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-026-07944-2
Rugo, Hope S; Pluard, T J; Sharma, P; Melisko, M; Al-Jazayrly, G; Ji, Y; Vidula, N; Ellerton, J; Smakal, M; Zimovjanova, M; Weng, D
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer

H3B-6545治疗局部晚期/转移性雌激素受体阳性、HER2阴性乳腺癌女性患者的I/II期研究

期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-025-02069-8
Hamilton, Erika; Pluard, Timothy; Wang, Judy S; Morikawa, Aki; Johnston, Stephen; Dees, E Claire; Vaklavas, Christos; Armstrong, Anne; Munster, Pamela; Unni, Nisha; Wright, Gail S; Kayali, Fadi; Song, Tingting; Rong, Yuanxin; Yamaguchi, Kohei; Juric, Dejan
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results

帕拉塞群（Palazestrant）是一种新型口服完全雌激素受体拮抗剂（CERAN）和选择性雌激素受体降解剂（SERD），用于治疗ER+/HER2-晚期或转移性乳腺癌患者：1/2期研究结果

期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-025-02049-y
Hamilton, Erika P; Patel, Manish R; Borges, Virginia F; Meisel, Jane L; Okera, Meena; Alemany, Carlos A; Pluard, Timothy J; Wesolowski, Robert; Sabanathan, Dhanusha; Miller, Kathy D; Conlin, Alison K; McCarthy, Nicole; Shaw, Morena; Tonda, Margaret; Shilkrut, Mark; Lin, Nancy U
肿瘤
HER2
肿瘤免疫
RAN
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Relationship of Prior Anticancer Treatments with Palbociclib Clinical Outcomes in Patients with HR(+)/HER2(-) Advanced Breast Cancer in Real-World Settings

既往抗癌治疗与帕博西尼治疗HR(+)/HER2(-)晚期乳腺癌患者真实世界临床疗效的关系

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-025-01158-0
Rocque, Gabrielle B; Blum, Joanne L; Ji, Yan; Pluard, Timothy; Migas, John; Lakhanpal, Shailendra; Jepsen, Erin; Wang, Yao; Montelongo, Monica Z; Zhang, Zhe; Gauthier, Eric; Tripathy, Debu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: updated systematic review

CDK4/6抑制剂一线治疗HR+/HER2-晚期/转移性乳腺癌的真实世界疗效：最新系统评价

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1530391
Harbeck, Nadia; Brufsky, Adam; Rose, Chloe Grace; Korytowsky, Beata; Chen, Connie; Tantakoun, Krista; Jazexhi, Endri; Nguyen, Do Hoang Vien; Bartlett, Meaghan; Samjoo, Imtiaz A; Pluard, Timothy
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review

CDK4/6抑制剂在老年及有色人种HR+/HER2-晚期/转移性乳腺癌患者中的真实世界疗效和安全性：一项更新的系统性文献综述

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1577075
Harbeck, Nadia; Brufsky, Adam; Grace Rose, Chloe; Korytowsky, Beata; Chen, Connie; Tantakoun, Krista; Jazexhi, Endri; Nguyen, Do Hoang Vien; Bartlett, Meaghan; Samjoo, Imtiaz A; Pluard, Timothy
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS

接受帕博西尼联合内分泌治疗的 HR+/HER2- 晚期乳腺癌患者的真实世界生活质量：POLARIS 研究中的 EORTC QLQ-C30 结果

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-024-07524-2
Rocque, Gabrielle B; Blum, Joanne L; Ji, Yan; Pluard, Timothy; Migas, John; Lakhanpal, Shailendra; Jepsen, Erin; Gauthier, Eric; Wang, Yao; Montelongo, Monica Z; Cappelleri, Joseph C; Karuturi, Meghan S; Tripathy, Debu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS

帕博西尼联合激素治疗的真实世界疗效及其对患者生活质量的影响：POLARIS 研究结果的简明摘要

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2570468
Tripathy, Debu; Blum, Joanne L; McCune, Steven; Pluard, Timothy; Anderson, Daniel; Johnston, Abigail; Montelongo, Monica Z; Zhang, Zhe; Cappelleri, Joseph C; Gauthier, Eric; Rocque, Gabrielle B
免疫/内分泌
发表日期：2025
文献求助 收藏

Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2- Metastatic Breast Cancer

帕博西尼、阿贝西利和瑞博西尼在HR+/HER2-转移性乳腺癌患者中的医疗资源利用和成本比较

期刊:
影响因子:
doi:10.2147/CEOR.S496100
Pluard, Timothy J; Sandin, Rickard; Parikh, Rohan C; Ward, Melea Anne; Stansfield, Lindsay; Nham, Tram; Esterberg, Elizabeth; Cha-Silva, Ashley S; Shah, Bhavesh
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏